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Abstract 
Background 
As mortality from coronary heart disease (CHD) falls, years lived with disability 
increase.  Depression and anxiety are known indicators of poor outcomes in CHD, but 
most research has measured distress symptoms at one time point, often following acute 
events. Here we consider the long-term trajectories of these symptoms in established 
CHD, and examine their association to distinct measures of disability and impact on 
costs.   
Methods and results 
803 patients with diagnosis of CHD were recruited from primary care, and completed 
detailed assessments every 6 months for 3 years. Latent class growth analysis (LCGA) 
was used to identify 5 distinct symptom trajectories based on the Hospital Anxiety and 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
3 
 
Depression Questionnaire (HADS): ‘stable low’, ‘chronic high’, ‘improving’, ‘worsening’, 
and ‘fluctuating’. The ‘chronic high’ group had highest association with reporting of 
chest pain (RRR 5.8, CI 2.9 to 11.7), smoking (2.9, 1.1 to 6.3), and poorer physical (0.88, 
0.83 – 0.93) and mental (0.78, 0.73 – 0.84) quality of life. The ‘chronic high’ and 
‘worsening’ trajectories had significantly higher health-care costs over the ‘stable low’ 
trajectory (107.2% and 95.5% increase, respectively). In addition, our trajectories were 
the only significant variable associated with increased health-care costs across the 3 
years. 
Conclusions 
Symptoms of depression and anxiety are highly prevalent in stable CHD patients, and 
their long-term trajectories are the single biggest driver of health care costs. Managing 
morbidity in these patients, in which depression and anxiety play a key role in, should 
become the primary focus of policy makers and future clinical trials.  
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Introduction 
 
Depression and anxiety are highly prevalent in Coronary Heart Disease (CHD) [1] [2], 
and are associated with poorer quality of life [3],[4], poorer disease outcome [5], and 
higher all-cause mortality [6, 7].  Most studies linking depression and anxiety to poorer 
outcome in patients with CHD use a single, baseline measure taken usually following an 
acute event – either a myocardial infarction (MI) [8] or interventions such as  bypass 
grafts [9]. Depression and anxiety are chronic, fluctuating conditions, and single 
measures do not provide sufficient information on the course or associated burden of 
these conditions over time [10]. Further, associations between depression, anxiety, and 
cardiovascular outcomes are likely to be reduced due to regression dilution bias [11]. 
Some studies have measured multiple time points of depression [12, 13] or anxiety,[14], 
finding persistent symptoms to be more predictive of adverse events and mortality, but 
these have also been done following an acute event, where the symptoms of depression 
and anxiety are likely to be exacerbated and directly related to the underlying event. 
This has failed to acknowledge the chronicity of these symptoms at the primary care 
level, where these patients mostly reside.   The case for interventions in patients with 
this mental-physical comorbidity will largely be determined by their likely impact on 
healthcare costs. There is limited information on the costs associated with depression 
or anxiety comorbid with CHD, with one study suggesting depression increases 
cardiovascular costs over five years from 15-50%[15]. In this study we use advanced 
longitudinal data analyses, which have previously been used to describe trajectories of 
depression and anxiety symptoms over time in general population samples [16] [17] 
and primary care settings [18], to: (i) identify, measure, and group the trajectories of 
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symptoms of depression and anxiety experienced by patients with CHD; (ii) measure 
which demographic, cardiac, social, and psychological risk factors are associated with 
these trajectories, in particular to test the extent to which more severe and prolonged 
symptoms of anxiety and depression are associated with underlying CHD disease 
severity, and (iii) measure the differences in health care costs between the trajectory 
groups. 
 
Methods 
 
We analysed a cohort of 803 patients with CHD recruited from 16 general practice (GP) 
surgeries in South East London, using data derived from the UPBEAT-UK project [19]. 
The aims of the original project were to understand further the relationship between 
depression and anxiety in a representative prevalent sample of people with CHD 
recruited from primary care. We were required to follow an opt-in procedure, and after 
initial contact by their GPs, 90% of those who responded agreed to participate in the 
study after meeting with our research team. These patients were followed-up for three 
years, undergoing assessments every six months. A baseline assessment which included 
measures of common mental disorders using the Clinical Interview Schedule - Revised 
(CIS-R), depression and anxiety using the Hospital Anxiety and Depression scale 
(HADS), as well as the Patient Health Questionnaire (PHQ-9), chest pain (Rose Angina 
Questionnaire), quality of life using the 12-item Short Form Survey (SF-12), social 
problems using the Social Problem Questionnaire (SPQ), and costs using the Client 
Service Receipt Inventory (CSRI), was applied during a face to face interview. 
Subsequently, bi-annual telephone interviews were conducted from six to 36 months 
after baseline assessment, which included all the above questionnaires with the 
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exception of the CIS-R. At the end of the study, each patient had data from up to seven 
unique time points comprising a three-year follow-up period from 2008-2011.  
 
Using these data, we ran a latent class growth analysis (LCGA) [20] using longitudinal 
HADS scores as the main outcome variable across time. We have previously found the 
HADS to have a good sensitivity and specificity to detect anxiety and depression in CHD 
compared with the criterion of the CIS-R (using a cut-off of 12) [4]. Furthermore, the 
HADS has been shown to be a marker of general distress combining depression and 
anxiety [21]. Thus, we modelled the trajectories of the symptoms of depression and 
anxiety according to the total HADS score, from baseline to 36 months.  
LCGA is a particular type of latent class analysis which uses growth mixture modelling 
techniques to identify individual growth trajectories in a sample across unobserved 
subpopulations (the categorical latent variables). These growth trajectories have 
different growth parameters (i.e. intercept and slope), and LCGA identifies those which 
have more in common with each other and classifies them into groups. Each group, or 
latent class, has a particular growth trajectory, and thus all individual growth 
trajectories within a particular class are homogeneous [20]. The LCGA model deals with 
missing data by using the maximum likelihood algorithm, which uses known data to 
estimate unknown parameters, by finding the values that maximize the probability of 
obtaining the observed data parameters. 
Deciding the optimal number of latent classes for the LCGA model is informed by 
established fit indices. As there is not an established guideline for determining which fit 
indices are optimal, it is best to use several, in addition to taking into account one’s own 
theoretical framework, interpretability, clinical translation, and other factors such as 
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having no less than 1% of the total sample in a single class [20].  We first ran a single-
class growth model with random intercept and random slope for the subjects, to test 
whether a linear, quadratic, or cubic model would be more appropriate to capture the 
overall observed pattern of the trajectory. The coefficient of the cubic term was not 
significant, and the quadratic curve gave a better fit than the linear curve, therefore we 
fitted a quadratic LCGA model. We then constructed latent class models with increasing 
number of classes (from three up to seven), and assessed goodness-of-fit using Bayesian 
information criteria (BIC), the Lo-Mendell-Rubin test (LMR-LRT), and the Bootstrap 
likelihood ratio test (BLRT) on each model to determine the optimal number of classes, 
maintaining the requirement that they translate to trajectory classes with clear clinical 
interpretations.  
Once the optimal number of classes was determined, the probabilities of each individual 
to belong to each of the latent classes were calculated using maximum posterior 
probabilities, and in this way each individual was assigned to one of the identified 
groups. We then used the latent classes as a categorical outcome variable to test for 
association with a variety of risk factors, using multinomial logistic regression analysis. 
First, we ran the model with our demographic variables, and then we controlled for 
these to test for the association with measures of cardiac risk factors, comorbidities, 
social problems, quality of life, and psychological factors.  
 
We also compiled the GP medical notes for each individual patient, comprising the 
entire 3-year follow-up period. For this study, we identified any mention of active 
management of depression and/or anxiety, either through primary care service s, or by 
referral to a specialist mental health service. This was done with the aim of identifying 
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how many patients in each class were recognised as having symptoms of depression 
and/or anxiety throughout our study period. 
Finally, we used the cost analysis gathered throughout the cohort study by the CSRI to 
identify which class had the lowest and highest costs across different service domains, 
which include primary, secondary, and informal (day-to-day carer) costs. The primary 
care costs (comprising GP, practice nurse, and community nurse contacts) are added to 
the secondary care costs (comprising inpatient and outpatient visits) to make up the 
total healthcare costs. When adding the informal costs (consisting in assistance of daily 
activities by carers specifically because of their health problems), the result is the total 
societal cost.  We then ran a regression analysis to determine the difference in mean 
costs between the classes, and whether these differences were significant after 
controlling for demographic, risk factor, and disease severity variables. These numbers 
are reported in Pounds Sterling (£), and taken from the Unit Cost of Health and Social 
Care 2012 and NHS Reference Costs 2011-12. 
 
The LCGA models were estimated using Mplus 8, whilst the regression analyses were 
performed in Stata 14. 
 
 
Results  
 
The characteristics of the overall sample have been described elsewhere [22]. In 
summary, the population was mostly male (69.9%), white (87.3%), and retired (77.7%), 
with a mean age of 70.6 years. At baseline interview, 149 of 803 (18.6%) met criteria for 
a depressive or anxiety disorder according to the CIS-R. These were divided as follows: 
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54 had a mild, moderate or severe depressive episode, 29 had anxiety or panic disorder, 
and 66 had mixed anxiety and depression [19]. %). Retention during 3-year follow-up 
was high: the average follow-up time was 2.64 years and the median was 2.94 years. 
141 (17.9%) had missing data on one or more time points due to a decline to be 
interviewed or loss to follow-up. 44 died from cardiovascular causes during follow-up 
and 28 from other causes. Similar to previous work in this cohort which looked at 
variables related to missingness at each follow-up point [4], the only significant 
variables related to missing data were increasing age (after 2 years) and non-white 
ethnicity (after one year). 
 
Latent class growth analysis 
 
The five-class model yielded the optimal combination of statistical goodness-of-fit and 
clinical interpretation, as it had the highest entropy score (.854), a significant BLRT 
score (<0.001), a low LMR-LRT score (0.36), and a low BIC (27654.9). The 4-class 
solution had a higher BIC and lower entropy, and the clinical interpretation was not as 
robust. The 6 and 7 class solution model fit indices had the lowest entropy scores, in 
addition to having a less clear clinical interpretation, therefore overall were deemed 
weaker than the 5-class solution (Table 1). Figure 1 provides a graphical representation 
of the five different classes, where the individual patient trajectories, as well as the 
mean trajectory for each class, are shown, alongside the intercept, slope, and quadratic 
values.  The five classes were as follows: ‘stable low’ symptoms (n=558), ‘chronic high’ 
symptoms (n=55), high then ‘improving’ symptoms (n=15), low then ‘worsening’ 
symptoms’ (n=64), and ‘fluctuating’ symptomatology (n=111). 
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Table 2 summarises the characteristics of each class. Class 1, ‘Stable low’, comprised 
69.5% of the sample, and had a higher male, white, and older percentage of participants 
than the other classes. Patient in this class had consistently low scores of depression 
and anxiety (mean range of 4.4-5.4 HADS total score).  Class 2, ‘Chronic high’ had 
consistently high symptoms of depression and anxiety, with a mean HADS score ranging 
from 24.0 at baseline to 22.3 at 36 months.  This class had the highest percentage of 
current chest pain, low physical and mental quality of life, and proportion (89.1%) 
having a psychiatric disorder at baseline.   Class 3, ‘Improving’ was a small group of 15 
individuals with a marked decrease in their symptoms over the three-year follow-up. At 
baseline, the mean HADS score (24.3) was very similar to the ‘chronic high’ class, and 
yet the patients on this class had a marked decrease in their symptoms, reaching a mean 
of 8.2 at 36 months.  This group had the highest percentage of recent life events and 
social problems at baseline.  Members of this class were also relatively young, better 
educated, and appeared to have less severe disease (e.g. fewer comorbidities and 
cardiac interventions).  Class 4, ‘Worsening’ showed deteriorating HADS scores over the 
follow up period. This class had the highest percentage of non-white ethnicity.  Finally, 
Class 5, ‘Fluctuating’ consisted of individuals who hovered around the cut-off point 
through the follow-up period. This class had the lowest proportion of males, the highest 
percentage of participants who were divorced or widowed and was the least educated 
group.  
 
Multinomial logistic regression analysis 
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In the logistic regression analysis, the comparison group was the ‘stable low’ class. 
Therefore, we measured the effect each variable had on the relative risk (RR) of 
belonging to a class as opposed to the ‘stable low’ class. 
 
 
 
Demographics 
 
Table 3a describes the (mutually adjusted) association between class membership and 
socio-demographic variables. Compared with the ‘stable low’ class, the symptomatic 
classes were younger (with the largest effect amongst the ‘chronic high’ class), and had 
higher proportions of women, (with the largest effect in the ‘fluctuating’ class). They 
were also associated with non-white ethnicity (particularly the ‘worsening’ class), and 
less years of education completed (significant among the ‘fluctuating’ and ‘worsening’ 
classes). Patients in the ‘fluctuating’ and ‘chronic high’ classes were more likely to be 
separated/widowed, an effect not seen in the other symptomatic classes. 
 
Cardiac risk factors and comorbidities 
 
Controlling for all demographic variables, associations with cardiac risk factors and 
comorbidities are shown in Table 3b.  Compared with the ‘stable low’ class, the 
symptomatic classes were associated with being a current smoker, and having chest 
pain (with particularly strong associations for the ‘chronic high’ class). However, other 
measures of disease severity, notably a history of myocardial infarction or heart failure, 
were not associated with class membership. The pattern for comorbidity was 
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inconclusive. Compared with the stable low group, there were no statistically significant 
associations with comorbid disease, although some of the results showed relatively 
large effect sizes, but with wide confidence intervals (e.g. the association between the 
‘improving’ class and diabetes and cancer). However, there was no evidence that the 
symptomatic classes experienced more multi-morbidity than the ‘stable low’ class. 
 
Disability and psychological factors  
 
Table 3c describes the association of social problems, quality of life, and mental health 
variables. The multivariable model we ran for these variables also was controlled for 
demographics, and additionally controlled for smoking and chest pain, since these were 
significantly associated to our latent classes as described above. Social problems were 
associated with the ‘chronic high’ class and with the ‘worsening’ class, however there 
was no difference between classes in terms of recent adverse life events. The physical 
component of quality of life was lower in all classes except for the ‘improving’ class, 
with the strongest effect on the ‘chronic high’ class. Finally, there was no association 
between reported life-time history of depressive episodes and class membership, 
however, unsurprisingly; there were very strong associations between baseline 
psychiatric diagnosis and membership in any of the symptomatic classes. Similarly, 
there was a strong association with mental components of quality of life.   
 
Examination of medical notes for depression and anxiety 
 
After examination of GP medical notes for each patient, we identified the number of 
patients per class which had either a referral to a mental health specialist, or active 
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management of depression or anxiety by their GP. The results were as follows: 77/558 
patients in the ‘stable low’ class were identified in this manner, amounting to 13.8% of 
the class total. The ‘chronic high’ class had 30/55 (54.5% of the total), the ‘improving’ 
class had 4/15 (26.7% of the total), the ‘worsening class’ had 31/64 (48.4% of the 
total), and the ‘fluctuating’ class had 40/111 (36.0% of the total).    
 
Health-care costs 
 
Table 4 describes the differences in mean costs across the three-year follow-up for each 
class.  The highest costs across all domains were in the ‘chronic high’ class (mean of 
£9,613 total societal costs), and in the ‘worsening’ class (mean of £9,073 total societal 
costs). This contrasted sharply to the classes with the lowest total societal costs: th e 
‘stable low’ class had a mean of £4,640 and the ‘improving’ class had a mean of £3,791. 
Thus, the average cost of a patient on the ‘chronic high’ class was approximately double 
that of a patient on the ‘stable low’ class. A subgroup analysis of costs, using the data on 
mental health service use gathered from the GP notes, found that in the ‘chronic high’ 
class, the patients with referrals to psychiatry services or under management of 
depression by their GP had lower mean societal costs (£8,127) than those who did not 
(£11,396). The subgroups using mental health services in the other four classes had 
higher mean costs than those not using these services.  Thus, patients with unidentified 
chronic depression/anxiety were the subgroup with highest health care costs overall.  
 
We also calculated the median costs, to counter the skewed nature of cost data, and 
again the highest costs across all domains (primary, secondary, total healthcare and 
total societal costs) were in the ‘chronic high’ (median total societa l cost £4,421) and 
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‘worsening’ (median total societal cost £4,148) classes. These costs are over 2 times 
higher than in the ‘stable low’ class (median total societal cost £2,097.6). Meanwhile, the 
costs for the ‘fluctuating’ (£2,411.1) and ‘improving’ (£2,200.6) classes were similar to 
the ‘stable low’ class.   
 
The regression analysis (Table 4) showed significantly higher total societal costs across 
the three-year period for patients on the ‘chronic high’ class and ‘worsening’ class, as 
compared to the ‘stable low’ class. This held after adjusting for demographic, social, risk 
factor and disease severity variables. In the model, all variables aside from the latent 
classes mentioned above were non-significant predictors for costs.  
 
Discussion 
 
We described five trajectories of symptoms of depression and anxiety in CHD patients 
across a three-year period with 7 unique time points. These trajectories showed distinct 
patterns of psychiatric morbidity, and compared with the ‘stable low’ group had an 
association to specific demographic, lifestyle, disability, and chest pain risk factors.  
There were substantial differences in health-care costs between the trajectories across 
the follow-up period. 
 
Thirty one percent of participants reported high depression and anxiety 
symptomatology either initially only (2%), increasingly (8%), continually (7%), or 
intermittently (14%). This highlights the prevalent, chronic, and unstable nature of 
affective symptoms in patients with CHD.  Whilst many associations with being in the 
symptomatic classes were expected (smoking, poorer quality of life, greater social 
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problems), it is noteworthy that none of the more objective measures of disease 
severity, psychiatric history, cardiac risk factors other than smoking, or comorbidities 
played a significant role.  However, reporting of chest pain was strongly associated with 
being in all the symptomatic groups, save the ‘improving’ class. This reflects a recent 
finding which identifies a strong association between depression and angina 
independent of cardiac severity [23].  Our data show that only a minority of individuals 
with symptoms of anxiety and depression received any specific interventions , which 
may be due to underreporting of symptoms by the patients themselves, and perhaps to 
subthreshold symptoms not meeting diagnostic criteria that encourages the GP to 
suggest treatment.  At the same time, there were large differences in health-care costs 
between the symptomatic classes and the ‘stable low’ class , even after adjusting for 
chest pain and other variables, indicating that depression and anxiety symptoms are 
potentially modifiable determinants of costs. Our trajectories were indeed the only 
variable significantly associated with health-care costs across the three-year period. 
 
Strengths and limitations 
 
This is the first study to conduct longitudinal trajectory analysis of depression and 
anxiety symptoms in a representative primary care, CHD population. Previous studies 
that have done follow-ups of these symptoms in primary care have been limited to 
measuring two time points over a 3 month period [24, 25] . Similar growth models on 
CHD patients have been done posterior to a cardiac event, measuring symptoms up to 
12 months after an MI or CABG [14] [26],  and likely reflect more on the adjustment and 
reaction to the particular event. Growth models identifying trajectories of depression 
have also been used to find associations with future conditions such as dementia [27], 
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and a follow-up of the data used in our model could strengthen the association of late-
life depression to vascular dementia [28], given the mean age of our study population.   
A limitation of our study is the lack of objective clinical measures of heart disease that 
could have been used to further strengthen the results and identify key associations and 
differences between the distinct trajectories.  There were some missing data in 
measurements of HADS across time, however our model accounts for this.  The small 
number of patients in the ‘improving’ class reduces the precision of results, reflected in 
the wide confidence intervals pertaining to that class. Finally, we have used the HADS as 
our primary measure given its use of both depression and anxiety symptoms, as we 
have made the case that they should both be considered in assessing mental distress 
amongst CHD patients. Our intention was not to determine the trajectory of standalone 
depression or anxiety as defined by the DSM or ICD, thus we did not use the PHQ-9 for 
this analysis, as it would have restricted the discussion on the long-term trajectory of 
symptoms of distress in CHD. In a previous study we found the HADS was a better 
predictor of costs and quality of life than the PHQ-9 in our study population [4], 
theorising this finding being due to the inclusion of anxiety symptoms which also play 
an important role in the chronicity of living with CHD. 
 
Implications 
 
Existing studies surrounding the long-term effect of depression and anxiety in CHD 
mostly use a cut-off score taken from a validated scale. This fails to take into account the 
dimensionality of these conditions and is assuming an increased risk of mortality just by 
scoring one or a few points more on a scale, in which some symptoms could well be 
overlapping with the very condition (CHD) they are being related to. Studies which do 
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include a ‘subthreshold’ trajectory, together with a ‘persistent’ trajectory [29], are 
limited by cut-off points also, and its unlikely patients never waver from these limits 
across each of the time points measured.  The time periods used to define persistent 
depression/anxiety are often smaller to the ones largely understood to be necessary for 
clinical diagnosis (for example persistent anxiety across 3 months [30]), or have time 
periods too wide apart (e.g. 2 years) for accurate measurements of the effect mental 
disorders may have on a chronic condition or acute event as part of the condition [31].  
Finally, as mentioned previously, most studies measure depression and anxiety in 
hospitalised patients, either after experiencing and acute cardiac event, or scheduled for 
an intervention. The consequent follow-up across studies is usually intended to obtain 
mortality outcome data. However, trends of long-term survival after MI and 
revascularisation are indeed improving [32], and since most of these patients do 
survive, there is comparatively little analysis into the consequences of chronic 
symptoms of depression and anxiety on CHD patients’ everyday lives, or how much 
contribution these symptoms make on the costs which patients incur upon the health 
care system. Specifically, the question is what are these chronic symptoms actually 
telling us about patients’ experiences of living with CHD, and how much do they really 
fluctuate over time?   
 
This study sheds further light into the chronic and diverse nature of depression and 
anxiety symptomatology within a long-standing physical condition. It stresses the 
importance of long-term follow up of mood disorders in patients with CHD at the 
primary care level, and the limits in focusing on this comorbidity after an acute event in 
hospitalised patients.  The findings underscore the fluctuation and ever-changing nature 
of these symptoms, and  therefore studies which only report on a single measurement of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
18 
 
symptoms of depression and/or anxiety may be capturing transient states of mood 
instability, perhaps driven by a recent life event or sudden change in circumstances.   
 
Furthermore, it is worth noting that these are patients belonging to a primary care 
register, with chronic health conditions that demand consistent visits to their GP to 
manage their CHD and relevant comorbidities. However, despite consistent reporting of 
high depression and anxiety symptomatology to our research team, only 55% of 
patients in the ‘chronic high’ class, and only 48% of patients in the ‘worsening’ class, had 
a mention of these symptoms in their medical notes. In addition, those patients in the 
‘chronic high’ class not identified as having these symptoms by their GPs had the highest 
costs overall.  This suggests the identification of patients with physical and mental 
comorbidity is still lacking, and failure to identify these patients signifies a burden on 
individual morbidity, and an added burden on health care systems by means of 
increased costs.  
 
 
The optimal management of these patients remains unclear.  A recent review on 
collaborative care for depression and CHD did not find a sustained treatment effect on 
adverse cardiac events and mortality [33], but did show benefit in addressing 
depression symptoms.  Similar results have been found for diverse psychological 
treatments [34]. Our results suggest that the critical outcome for trials aimed at 
evaluating treatments for depression should be aimed at reducing healthcare costs 
associated with both depression and anxiety.  These may arise from better disease 
management and improved symptom control, leading to reduced service utilisation.  
Our findings demonstrate the chronic and fluctuating course of symptoms of depression 
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and anxiety in CHD. Therefore, treatment and management of this comorbidity should 
be able to adapt in line with the chronic and fluctuating nature of symptoms, as well as 
allow for identification of subthreshold symptoms that merit closer follow-up even 
without meeting strictly defined criteria.  This would in turn benefit the health care 
system as a whole, as we have shown depression and anxiety trajectories to be the 
biggest drivers of costs in long-term management of patients with this chronic physical 
condition.  
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Figures and tables 
 
 
 
 
 
 
Class 5: Fluctuating 
N: 111 
Intercept: 15.14 
Slope: -4.55 
Quadratic value: 1.29 
 
 
Class 2: Chronic high 
N: 55 
Intercept: 23.52  
Slope: -0.80 
Quadratic value: 0.19 
 
 
Class 3: Improving 
N: 15 
Intercept: 21.77 
Slope: -16.05 
Quadratic value: 4.03 
 
 
Class 4: Worsening 
N: 64 
Intercept: 10.79 
Slope: 4.63 
Quadratic value: -0.51  
 
 
Class 1: Stable low 
N: 558 
Intercept: 4.45 
Slope: 0.28 
Quadratic value: 0.04 
 
Figure 1: Individual patient trajectories of depression and anxiety symptoms across time, grouped according to latent classes   
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No. of classes BIC LMR-LRT  BLRT  Entropy 
3 27693.5 0.0537  <0.0001  0.842 
4 27667.9 0.0609  <0.0001  0.848 
5 27654.9 0.3674  <0.0001  0.854 
6 27650.2 0.4949  <0.0001  0.84 
7 27649.8 0.4262  <0.0001  0.84 
 
 
 
 
 
 
Table 1: Latent Class Growth Analysis model fit statistics for different number of 
classes. BIC: Bayesian Information Criteria; LMR-LRT: Lo-Mendell-Rubin test; 
BLRT: Bootstrap likelihood ratio test. 
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Stable low            
(n = 558) 
Chronic high        
(n = 55) 
Improving          
(n = 15) 
Worsening          
(n = 64) 
Fluctuating             
(n = 111) 
Demographics % % % % % 
Age (mean) 72.3 years 64.0 years 59.5 years 68.0 years 71.6 years 
Male sex 74.7 67.3 60.0 64.1 51.3 
White ethnicity 90.5 81.8 80.0 71.9 83.8 
Divorced/widowed/separated 26.8 32.7 13.3 21.9 37.8 
12+ years education 55.4 50.0 60.0 45.2 41.7 
Cardiac risk factors      
Current smoker 9.0 29.1 33.3 20.3 17.1 
Overweight 47.6 19.6 33.3 36.5 42.6 
Obese 27.8 52.9 53.3 39.7 37.0 
Cardiac history      
History of MI 57.5 60.0 53.3 56.2 59.5 
Cardiac intervention 52.7 50.9 33.3 46.9 54.9 
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Heart failure 9.3 10.9 6.7 7.8 9.9 
Current chest pain 34.8 78.2 53.3 54.7 68.5 
Comorbidities      
Hypertension 54.8 56.4 46.7 56.2 58.6 
Diabetes 23.1 40.0 40.0 26.6 23.4 
COPD 9.7 14.5 13.3 12.5 17.1 
Cancer 12.0 7.35 13.3 9.4 15.3 
Multiple comorbidities 45.3 52.7 40.0 53.1 53.1 
Social Problems and life 
events 
     
No social problems 55.9 7.3 6.7 34.4 28.8 
One social problems 33.5 27.3 26.7 31.2 36.0 
2+ social problems 10.6 65.4 66.7 34.4 35.1 
Life event in past 6 months 55.0 67.3 80.0 60.9 63.1 
Quality of life      
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Mental Qol (mean score) 51.1 29.2 33.7 44.0 39.8 
Physical Qol (mean score) 40.0 30.4 37.2 33.8 33.8 
Psychiatric history      
One depressive episode 10.0 23.6 20.0 15.6 18.0 
Two or more dep. episodes 6.4 32.7 20.0 17.2 17.1 
Any CIS-R diagnosis 3.2 89.1 66.7 31.3 47.9 
 
 
 
 
 
 
 
Table 2: Comparison of descriptive baseline characteristics according to all five latent classes. Values are percentages unless otherwise stated.  
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 Chronic high      
(n=55) 
Improving        
(n=15)  
Worsening              
(n=64) 
Fluctuating             
(n=111) 
a)Demographics RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
Age group+ 0.4 (0.3 – 0.5)** 0.3 (0.1 – 0.5)** 0.6 (0.5 – 0.9)** 0.8 (0.6 – 1.0) 
Female sex 1.6 (0.9 – 3.1) 2.6 (0.9 – 7.9) 2.1 (1.2 – 3.8)* 2.6 (1.7 – 4.2)** 
Non-white ethnicity 1.8 (0.8 – 4.1) 1.7 (0.4 – 6.9) 4.5 (2.2 – 9.1)** 2.3 (1.2 – 4.4)** 
Widowed/divorced 1.7 (0.9 – 3.3) 0.5 (0.1 – 2.5) 0.9 (0.5 – 1.8) 1.4 (0.9 – 2.3) 
12 or more years education 0.6 (0.3 – 1.0) 0.7 (0.2 – 2.1) 0.4 (0.2 – 0.7)** 0.5 (0.3 – 0.8)** 
b) Cardiac risk/clinical     
Current smoker 2.9 (1.3 – 6.3)** 2.8 (0.7 – 10.7) 2.4 (1.1 – 5.2)* 2.0 (1.0 – 3.9)* 
Overweight / Obese 0.6 (0.3 – 1.4) 1.4 (0.3 – 6.8) 1.0 (0.5 – 2.0) 1.3 (0.8 – 2.3) 
History of MI 1.0 (0.6 – 1.5) 0.8 (0.3 – 1.8) 1.1 (0.7 – 1.5) 1.0 (0.7 – 1.3) 
Previous cardiac intervention 0.9 (0.5 – 1.7) 0.4 (0.1 – 1.3) 1.0 (0.6 – 1.7) 1.5 (1.0 – 2.4) 
Heart failure 1.9 (0.7 – 5.2) 1.4 (0.1 – 14.3) 1.1 (0.4 – 3.2) 1.0 (0.5 – 2.2) 
Current chest pain 5.8 (2.9 – 11.7)** 1.6 (0.5 – 4.9) 1..7 (1.0 – 3.0)* 3.5 (2.2 – 5.6)** 
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Hypertension 1.1 (0.5 – 2.3) 1.0 (0.3 – 3.8) 0.9 (0.5 – 1.7) 1.1 (0.6 – 1.8) 
Diabetes 2.1 (1.0 – 4.4) 4.1 (1.0 – 17.6) 0.9 (0.4 – 1.8) 1.0 (0.6 – 1.8) 
COPD 0.9 (0.3 – 2.7) 1.3 (0.2 – 9.5) 0.9 (0.3 – 2.4) 1.8 (0.9 – 3.7) 
Cancer 0.8 (0.2 – 2.4) 2.6 (0.4 – 14.4) 0.6 (0.2 – 1.6) 1.4 (0.7 – 2.7) 
2 or more comorbidities 1.4 (0.6 – 3.4) 0.5 (0.1 – 2.7) 1.4 (0.6 – 2.9) 0.9 (0.5 – 1.6) 
c) Social/psychological     
Social problems 1.7 (1.2 – 2.6)**  1.4 (0.9 – 2.4) 1.4 (1.0 – 1.9)* 1.2 (0.9 – 1.6) 
  Recent adverse life event 1.1 (0.4 – 3.4) 1.4 (0.2 – 8.8) 0.8 (0.4 – 1.6) 1.1 (0.4 – 3.4) 
Quality of life – physical 0.88 (0.83 – 0.93)** 0.98 (0.90 – 1.06) 0.95 (0.92 – 0.98)** 0.95 (0.93 – 0.98)** 
History of depressive episodes 1.5 (0.5 – 4.0) 1.5 (0.4 – 6.3) 1.3 (0.6 – 2.8) 1.3 (0.7 – 2.5) 
Any CIS-R diagnosis  10.3 (2.9 – 37.0)** 9.6 (1.7 – 55.3)** 2.5 (1.0 – 6.1)* 5.9 (2.7 – 13.1)** 
Quality of life – mental 0.78 (0.73 – 0.84)** 0.82 (0.74 – 0.90)** 0.92 (0.88 – 0.96)** 0.89 (0.86 – 0.92)** 
Table 3: Multinomial logistic regression analysis of a) demographic, b) cardiac and clinical (adjusted for demographic), and c) social and psychological (adjusted for 
smoking and chest pain) variables as risk factors for class membership. Reference class is ‘stable low’ * significant at .05 level, ** significant at .01 level 
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 Stable low Chronic high Improving Worsening Fluctuating 
Primary care (SE) 512.2 (27.3) 750.5 (99.5) 486.4 (81.1) 873.3 (434.3) 592.8 (61.1) 
Secondary care 
(SE) 
3,599.9 (281.2) 7,719.0 (2,295.7) 2,599.7 (738.3) 7,085.6 (1,728.4) 4,234.4 (767.8) 
Total healthcare 
(SE)  
4,549.6 (315.9) 9,311.9 (2,415.6) 3,654.6 (852.1) 8,880 (1,936.3) 6,187.5 (959.2) 
Total societal (SE) 4,640.4 (318.6) 9,613,3 (2,431.3) 3,791.1 (903.4) 9,073.8 (5,187.5) 6,442.2 (973.3) 
Adjusted* mean 
difference in total 
societal costs (95% 
CI) 
Ref 
5,136.8 (2,224.1 to 
8,049.5)** 
-369.3 (-5,536.9 to 
4,798.3) 
4,746.7 (2,073.3 to 
7,420.1)** 
1,790.3 (-344.2 to 
3,924.9) 
 
 
 
  
Table 4: Mean costs (GBP) (SE) across time for each latent class, and difference in total societal mean costs across 3-year follow-up for each latent class 
group as compared to the ‘stable low’ group.  
*Adjusted for demographics (sex, age, ethnicity), social variables (relationship, education status), risk factors (smoking, BMI, documented MI), multiple 
comorbidities, and experience of chest pain. **significant at .01 level 
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Highlights 
 803 primary care patients with CHD were followed-up every 6 months for 3 years 
 Latent class growth analysis determined depression and anxiety symptom trajectories 
 Stable low, chronic high, worsening, improving, and fluctuating groups were found  
 Chronic high group associated with poorer quality of life, increased costs 
 Trajectories only variable significantly associated to higher health-care costs  
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